ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

IMMX Immix Biopharma Inc

2.45
0.10 (4.26%)
Fuera de horario
Última actualización: 16:17:14
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Immix Biopharma Inc IMMX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.10 4.26% 2.45 16:17:14
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.35 2.26 2.50 2.33 2.35
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
07/2/202416:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/2/202408:09EDGAR2Form 8-K - Current report
05/2/202415:38EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/2/202415:37EDGAR2Form 8-K - Current report
12/12/202317:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202309:48IHNWImmix Biopharma Announces FDA Approval of IND Application..
09/11/202318:57EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
25/9/202315:15EDGAR2Form S-3 - Registration statement under Securities Act of..
18/9/202318:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/9/202317:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202315:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/8/202315:15EDGAR2Form SC 13D - General statement of acquisition of beneficial..
23/8/202315:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202315:05EDGAR2Form 8-K - Current report
14/8/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/8/202315:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
25/7/202307:42GLOBEImmix Biopharma Subsidiary Nexcella Announces NXC-201..
17/7/202308:37GLOBEImmix Biopharma Reports 2nd Positive Interim Clinical Trial..
14/7/202316:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/7/202316:26EDGAR2Form 8-K - Current report
10/7/202308:47GLOBEImmix Biopharma Subsidiary Nexcella Completes Initial..
26/6/202308:49GLOBEImmix Biopharma Subsidiary Nexcella Completes Pre-IND..
22/6/202308:53GLOBEImmix Biopharma Subsidiary Nexcella Appoints Edward J...
20/6/202308:45GLOBEImmix Biopharma Subsidiary Nexcella Appoints Jeffrey H...
16/6/202308:43GLOBEImmix Biopharma Subsidiary Nexcella Appoints Mary Sue..
14/6/202306:30GLOBEImmix Biopharma Completes $5 Million At-The-Market Equity..
12/6/202308:49GLOBEImmix Biopharma Subsidiary Nexcella Appoints Henry..
26/5/202308:53GLOBEImmix Biopharma Subsidiary Nexcella Announces Commencement..
21/5/202315:05GLOBENexcella Announces Positive NXC-201 Clinical Results at..
21/5/202315:00GLOBEImmix Biopharma Announces Positive NXC-201 Clinical Results..

Su Consulta Reciente

Delayed Upgrade Clock